Drug Profile


Alternative Names: DPP-IV(3); R 1579; RG 1579; RO 4876904-001

Latest Information Update: 22 Jan 2010

Price : $50

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class 3-ring heterocyclic compounds; Antihyperglycaemics; Pyrrolidinones; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 30 Sep 2007 Phase-II clinical trials in Type-2 diabetes mellitus in Europe (PO)
  • 19 Sep 2006 Phase-I clinical trials in Type-2 diabetes mellitus in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top